Outcomes From Two New Head-to-Head Randomized Controlled Trials Involving the UroLift™ System Highlight a Superior Patient Experience* Against Rezūm and Its Advantage Over Medical Therapy as an Early Intervention for BPH
“For over 10 years, Teleflex has advanced BPH research through numerous trials involving the UroLift™ system and now other contemporary treatments.
- “For over 10 years, Teleflex has advanced BPH research through numerous trials involving the UroLift™ system and now other contemporary treatments.
- ***5
Once procedure volume is factored in, the UroLift™ System has the lowest rates of mild, moderate, and severe postoperative complications on a per case basis from 2019 to 2022 in the MAUDE database. - The goal is for the provider and patient to decide whether to continue, stop, or switch to another therapy based on the symptomatic response of medication.
- **9 It is the only leading enlarged prostate procedure that does not require heating, cutting, or destruction of prostate tissue.10-11
For more information about the UroLift™ System, visit www.UroLift.com .